Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

406 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK.
Ewenstein BM, Collins P, Tarantino MD, Negrier C, Blanchette V, Shapiro AD, Baker D, Spotts G, Sensel M, Yi SE, Gomperts ED. Ewenstein BM, et al. Among authors: blanchette v. Semin Hematol. 2004 Jan;41(1 Suppl 2):1-16; discussion 16-8. doi: 10.1016/s0037-1963(04)00017-4. Semin Hematol. 2004. PMID: 15071785
Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens.
Collins PW, Björkman S, Fischer K, Blanchette V, Oh M, Schroth P, Fritsch S, Casey K, Spotts G, Ewenstein BM. Collins PW, et al. Among authors: blanchette v. J Thromb Haemost. 2010 Feb;8(2):269-75. doi: 10.1111/j.1538-7836.2009.03703.x. Epub 2009 Nov 23. J Thromb Haemost. 2010. PMID: 19943875 Free article.
Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.
Björkman S, Blanchette VS, Fischer K, Oh M, Spotts G, Schroth P, Fritsch S, Patrone L, Ewenstein BM; Advate Clinical Program Group; Collins PW. Björkman S, et al. Among authors: blanchette vs. J Thromb Haemost. 2010 Apr;8(4):730-6. doi: 10.1111/j.1538-7836.2010.03757.x. J Thromb Haemost. 2010. PMID: 20398185 Free PMC article.
The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report.
Valentino LA, Carcao M, Mathew P, Leissinger CA, Berntorp E, Blanchette V, Escuriola-Ettingshausen C, Ewenstein B, Ewing N, Gringeri A, Hoots WK, Negrier C. Valentino LA, et al. Among authors: blanchette v. Haemophilia. 2009 Jul;15(4):959-65. doi: 10.1111/j.1365-2516.2008.01953.x. Epub 2009 Mar 23. Haemophilia. 2009. PMID: 19320750 No abstract available.
Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH.
Iorio A, Blanchette V, Blatny J, Collins P, Fischer K, Neufeld E. Iorio A, et al. Among authors: blanchette v. J Thromb Haemost. 2017 Dec;15(12):2461-2465. doi: 10.1111/jth.13867. Epub 2017 Nov 9. J Thromb Haemost. 2017. PMID: 29119666 Free article. No abstract available.
406 results